Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour

Luca Antonelli^{1

2}, Axel Heidenreich^{3

4}, Aditya Bagrodia^{5

6}, Armon Amini^{5

6}, Fady Baky^{5

6}, Nicolas Branger⁷, Walter Cazzaniga⁸, Timothy N Clinton⁹, Siamak Daneshmand¹⁰, Hooman Djaladat¹⁰, Scott Eggener¹¹, Alireza Ghoreifi¹⁰, Robert J Hamilton¹², Matthew Ho¹¹, Wade J Sexton¹³, Sebastiano Nazzani¹⁴, David Nicol^{8

15}, Nicola Nicolai¹⁴, Kathleen Olson¹⁶, Pia Paffenholz³, James Porter¹⁷, Zhiyu Qian⁹, Nicholas R Rocco¹⁸, Anirudh Yerrapragada¹⁹, Sean P Stroup¹⁸, Isamu Tachibana²⁰, Angelika Terbuch²¹, Nirmish Singla¹⁹, Clint Cary²⁰, Christian D Fankhauser^{1

22}; EAU‐YAU Penile and Testis Cancer Working Group

Affiliations

¹ Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
² Department of Urology, Policlinico Umberto I, Sapienza University, Rome, Italy.
³ Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁴ Department of Urology, Medical University, Vienna, Austria.
⁵ Department of Urology, Univerity of California, San Diego, CA, USA.
⁶ The University of Texas Southwestern, Dallas, TX, USA.
⁷ Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France.
⁸ Department of Urology, The Royal Marsden NHS Foundation Trust, London, Sutton, UK.
⁹ Department of Urology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁰ Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹¹ Section of Urology, Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA.
¹² Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
¹³ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
¹⁴ Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁵ Institute of Cancer Research, London, UK.
¹⁶ Department of Urology, Mayo Clinic, Scottsdale, AZ, USA.
¹⁷ Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
¹⁸ Department of Urology, Naval Medical Center, San Diego, CA, USA.
¹⁹ Department of Urology and Oncology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
²⁰ Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
²¹ Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
²² University of Zurich, Zurich, Switzerland.

PMID: 39662898
DOI: 10.1111/bju.16618

Multicenter Study

Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour

Luca Antonelli et al. BJU Int. 2025 Apr.

. 2025 Apr;135(4):621-628.

doi: 10.1111/bju.16618. Epub 2024 Dec 11.

Authors

Affiliations

¹ Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
² Department of Urology, Policlinico Umberto I, Sapienza University, Rome, Italy.
³ Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁴ Department of Urology, Medical University, Vienna, Austria.
⁵ Department of Urology, Univerity of California, San Diego, CA, USA.
⁶ The University of Texas Southwestern, Dallas, TX, USA.
⁷ Department of Surgical Oncology 2, Institut Paoli-Calmettes, Marseille, France.
⁸ Department of Urology, The Royal Marsden NHS Foundation Trust, London, Sutton, UK.
⁹ Department of Urology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁰ Institute of Urology, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
¹¹ Section of Urology, Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA.
¹² Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
¹³ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
¹⁴ Urologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁵ Institute of Cancer Research, London, UK.
¹⁶ Department of Urology, Mayo Clinic, Scottsdale, AZ, USA.
¹⁷ Department of Urology, University of Washington School of Medicine, Seattle, WA, USA.
¹⁸ Department of Urology, Naval Medical Center, San Diego, CA, USA.
¹⁹ Department of Urology and Oncology, The James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
²⁰ Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
²¹ Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
²² University of Zurich, Zurich, Switzerland.

PMID: 39662898
DOI: 10.1111/bju.16618

Abstract

Objectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications.

Materials and methods: Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease-free survival (DFS).

Results: A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01-1.07; P = 0.03), but no association was observed with DFS. The 5-year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non-teratomatous viable cancer in the RPLND specimen, the 5-year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS.

Conclusions: Our study suggests considering primary RPLND not only in marker-negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker-positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.

Keywords: adjuvant chemotherapy; non‐seminomatous germ cell tumour; primary retroperitoneal lymph node dissection; testis cancer; viable germ cell tumour.

PubMed Disclaimer

References

1. Nason GJ, Hamilton RJ. Robotic RPLND for stage IIA/B nonseminoma: the Princess Margaret experience. World J Urol 2022; 40: 335–342
1. Weissbach L, Bussar‐Maatz R, Flechtner H, Pichlmeier U, Hartmann M, Keller L. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000; 37: 582–594
1. Lauritsen J, Hansen MK, Bandak M et al. Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol 2020; 38: 584–592
1. Carver BS, Sheinfeld J. Postchemotherapy surgery for germ cell tumors of the testis. Curr Opin Oncol 2011; 23: 271–274
1. Stephenson AJ, Aprikian AG, Gilligan TD et al. Management of low‐stage nonseminomatous germ cell tumors of testis: SIU/ICUD consensus meeting on germ cell tumors (GCT), Shanghai 2009. Urology 2011; 78(4 SUPPL): S444–S455

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour

Affiliations

Primary retroperitoneal lymph node dissection in clinical stage 2a/b non-seminomatous germ cell tumour

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical